We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
8/29/2012 WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare Conference at the New York Palace Hotel in New York on Thursday, September 6, 2012 at 2:00 p.m. EDT. Also, the Company announced that Mr. Moulder will be...
7/26/2012 Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC MeetingsIn-Licensed Niraparib, a Potentially First and Best-in-Class PARP InhibitorRaised Over $86.8 Million in Gross Proceeds from an Initial Public Offering WALTHAM, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) an oncology-focused biopharmaceutical compa...
7/24/2012 WALTHAM, Mass., July 24, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the underwriters of its initial public offering have partially exercised their over-allotment option for the purchase of an additional 430,183 shares of TESARO common stock. All of such shares were sold by TESARO at the initial public offering price of...
7/19/2012 WALTHAM, Mass., July 19, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2012 financial results on Thursday, July 26th, 2012, before the open of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, July 26th, at 8:30 a.m. ET to discuss the Company...
6/27/2012 WALTHAM, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $13.50 per share. The shares of TESARO's common stock have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading tomorr...
9/06/2011
6/21/2011
3/22/2011
12/14/2010
5/26/2010 Boston, MA – May 26, 2010 – TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics and supportive care products. Participants in a $20 million Series A financing included New Enterprise Associates (NEA) an...
Page:
...
Next Last
 
= add release to Briefcase